Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Curent Deferred Tax Liability Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Usana Health Sciences (USNA) Operating Leases (2021 - 2022)

Usana Health Sciences has reported Operating Leases over the past 2 years, most recently at $7.1 million for Q1 2022.

Quarterly Operating Leases fell 17.83% to $7.1 million in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $7.1 million through Jan 2022, down 17.83% year-over-year, with the annual reading at $7.1 million for FY2022, 17.83% down from the prior year.
Operating Leases was $7.1 million for Q1 2022 at Usana Health Sciences, down from $8.6 million in the prior quarter.
Over five years, Operating Leases peaked at $8.6 million in Q1 2021 and troughed at $7.1 million in Q1 2022.